DA 3003-2
DA 3003-2 is a potent and selectively Cdc25 inhibitor. DA 3003-2 shows antiproliferative activity. DA 3003-2 induces cell cycle arrest at the G2/M phase and increases the expression of P-tyr15 Cdc2. DA 3003-2 has the potential for the research of prostate cancer[1].
Product Specifications
CAS Number
383907-47-9
Product Name Alternative
NSC663285
UNSPSC
12352005
Target
Phosphatase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/da-3003-2.html
Purity
98.36
Solubility
DMSO : 150 mg/mL (ultrasonic)
Smiles
O=C(C1=C(C2=O)N=CC=C1)C(NCCN3CCOCC3)=C2Cl
Molecular Formula
C15H16ClN3O3
Molecular Weight
321.76
References & Citations
[1]Nemoto K. G2/M accumulation in prostate cancer cell line PC-3 is induced by Cdc25 inhibitor 7-chloro-6- (2-morpholin-4-ylethylamino) quinoline-5, 8-dione (DA 3003-2) . Exp Ther Med. 2010 Jul;1 (4) :647-650.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15097736 1 Vial
Lentiviral human RETSAT shRNA (UAS) - Lentiviral human RETSAT shRNA (UAS, GFP) (25)
Sign In for Pricing
View Details